The revival of Phage Therapy to fight Antimicrobial Resistance – Part I: What are the legal implications?

Søgeresultater

• Locus licenses CRISPR tech to Janssen in potential $818m deal

  Minssen, T.

  09/01/2019

  1 Mediebidrag

  Presse/medie